article · African Journal of Biomedical Research
Background: Chronic diarrhea, defined as three or more abnormally loose stools lasting at least four weeks, affects approximately 5% of adults worldwide and poses significant diagnostic and therapeutic challenges. This study aims to evaluate the epidemiological characteristics, management strategies, and outcomes of patients with chronic diarrhea treated at Tanta University Hospitals. Methods: This retrospective study included 854 patients aged >18 years with chronic diarrhea between January 2018 and October 2023. Data on demographics, clinical presentation, laboratory findings, diagnostic modalities, treatment approaches, and outcomes were extracted and analyzed using R and Jamovi software. Results: The mean age was 40.32 ± 17.29 years, with 54.1% males. Common comorbidities included hypertension (17.6%) and diabetes mellitus (15.7%). Functional disorders were the leading cause (28.68%), followed by ulcerative colitis (18.97%) and drug-induced diarrhea (6.44%). Most patients (91%) were managed medically, with 4.7% requiring surgical intervention. Outcomes included improvement in 45.2%, remission in 23.8%, and cure in 10.8%. Relapse occurred in 7.9%, progression in 3.6%, and death in 2.6%. Conclusion: Functional disorders and inflammatory bowel diseases were the most common causes of chronic diarrhea. Medical management was the predominant treatment approach, yielding favorable outcomes in the majority of cases. Improved diagnostic accuracy and tailored therapeutic strategies are essential to optimize patient outcomes.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.53555/ajbr.v28i1s.6482
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.